Cardiac Pacemakers, Inc.

Incon-trol Corp.

Physio-control, Inc.

Other

Purdue Research Foundation

Darrell Orvin Wagner

Adam W Cates

Apurv Ullas Kamath

Paul Allan Haefner

Marina V Brockway

Curtis Charles Lindstrom

Haris Sih

Robert Eugene Smith

Karl F Gauglitz

Stephen J Prosser

Peter W Cheung

Scott W Hunsaker

Ron Heil

John Mathew Adams

Eric G Lovett

Tamara Colette Baynham

Gregory M Ayers

Kenneth R Infinger

Lee R Mason

Clifton A Alferness

Robert J Sweeney

Joseph M Bocek

Ronald W Heil, Jr

William John Havel

Jason Alan Shiroff

Hugo Xavier Gonzalez

Steven D Girouard

Leslie A Geddes

Craig Michael Stolen

Jeffrey Ross

Joe D Bourland

Jihong Qu

Kristine M Larsen-Kelly

Willis A Tacker, Jr

Mike Favet

Jihong Ou

Willis A Tacker

Haris J Sih

Kenneth Ross Infinger

A system and device are provided which include a gene regulatory system controlling expression of one or more expression cassettes present in or released by the device, by emitting one or more stimulations. An expression cassette includes a regulatable transcription control element that is responsive to the emitted stimulations linked to an open reading frame of interest. The system optionally includes a sensor to sense a parameter indicative of a need, a telemetry module to receive an external command, or a programmable device, for regulating gene expression of the open reading frame.

Method of using a lead to regulate protein expression

A stimulation system delivers stimulation to protect an ischemic region of a body from tissue damage caused by ischemia. The stimulation is delivered to one or more stimulation sites remote from the ischemic region to elicit a physiological effect that protects the ischemic region from the tissue damage caused by ischemia. In one embodiment, the stimulation system delivers cardioprotective stimulation to one or more stimulation sites remote from the heart to protect the heart from injuries associated with cardiac ischemic events. In another embodiment, the stimulation system delivers remote conditioning stimulation to one or more stimulation sites in or on the heart to protect a non-cardiac region from injuries associated with non-cardiac ischemic events.

Method and apparatus for tissue protection against ischemia using remote conditioning

Cardiac systems and methods using ECG and blood information for arrhythmia detection and discrimination. Detection circuitry is configured to produce an ECG. An implantable blood sensor configured to produce a blood sensor signal is coupled to a processor. The processor is coupled to the detection and energy delivery circuitry, and used to evaluate and treat cardiac rhythms using both the cardiac electrophysiologic and blood sensor signals. The blood sensor is configured for subcutaneous non-intrathoracic placement and provided in or on the housing, on a lead coupled to the housing, and/or separate to the housing and coupled to the processor via hardwire or wireless link. The blood sensor may be configured for optical sensing, using a blood oxygen saturation sensor or pulse oximeter. A cardiac rhythm may be evaluated using the electrocardiogram signal and the blood sensor signal, and tachyarrhythmias may be treated after confirmation using the blood sense signal.

Subcutaneous cardiac sensing and stimulation system

A system for controlling the location of a therapeutic agent administered to a mammal is provided. The system employs a device that is capable of generating a magnetic field and a therapeutic agent labeled with a magnetically responsive moiety. Methods which employ the device and the therapeutic agent are also provided.

Methods to position therapeutic agents using a magnetic field

Subcutaneous cardiac sensing and stimulation system employing blood sensor

An implantable subcutaneous device includes a lead and electrode for cardiac monitoring and intervention. The device has an implantable lead including a lead body, a subcutaneous electrode supported by the lead body and a pharmacological agent impelled from the device using phoresis. The pharmacological agent provides a therapeutic treatment to subcutaneous non-intrathoracic tissue. A method of implanting subcutaneous leads involves providing a lead including a lead body, a subcutaneous electrode, and a pharmacological agent and using phoresis to impel the pharmacological agent into subcutaneous non-intrathoracic tissue surrounding the lead.

Subcutaneous electrode and lead with phoresis based pharmacological agent delivery

Systems and methods provide for sensing of cardiac activity from a subcutaneous, non-intrathoracic location, and detecting a cardiac condition necessitating treatment in response to the sensed cardiac activity. One of a number of cardiac therapies may be selectively delivered to treat the detected cardiac condition, such cardiac therapies including at least a tachycardia therapy, a bradycardia therapy, and an asystole prevention therapy.

Subcutaneous cardiac rhythm management with asystole prevention therapy

Cardiac methods and devices that separate signals using at least two composite signals acquired at least at two input impedances. A target source impedance may be selected, and a cardiac signal may be separated from composite signals using the selected target source impedance. Medical systems include a cardiac device having a housing that provides amplification circuitry configured to have a first amplifier input impedance and a second amplifier input impedance, such as using two separate circuits or switching between two input impedances. One or more electrode assemblies are coupled to the amplification circuitry. A signal processor is provided in the housing configured to separate a source signal using a first composite signal detected at the first input impedance and a second composite signal detected at the second input impedance. The phase response of the first input amplifier circuit is about equal to that of the second input amplifier circuit.

Biopotential signal source separation using source impedances

An implantable subcutaneous device and method employ a lead and an electrode for cardiac monitoring and intervention. The device includes an implantable lead having a lead body, a subcutaneous electrode coupled to the lead body, and a pharmacological agent provided on the implantable lead and/or electrode. The pharmacological agent provides a temporary therapeutic treatment to subcutaneous non-intrathoracic tissue. A method of implanting subcutaneous leads involves providing a lead including a lead body, a subcutaneous electrode, and a pharmacological agent, and delivering the pharmacological agent to subcutaneous non-intrathoracic tissue surrounding the lead.

Subcutaneous electrode and lead with temporary pharmacological agents

Implementing a subcutaneous medical electrode system involves positioning a number of electrode subsystems in relation to a heart so that noise cancellation provides an improved signal to noise ratio of the cardiac signal and/or to provide one electrode arrangement preferential for cardiac signals and another arrangement preferential for noise signals. One of the electrode subsystems so positioned may include one or more can electrodes located on a housing enclosing a medical device. The medical device may be configured to provide therapeutic, diagnostic, or monitoring functions, including, for example, cardiac arrhythmia therapy.

Noise canceling cardiac electrodes

Transthoracic cardiac stimulation therapies provide for detection and treatment of cardiac asystole subsequent to delivery of a defibrillation therapy. A pacing therapy is transthoracicly delivered to terminate detected cardiac asystole using residual energy from a defibrillation energy storage source. The residual energy usable for the pacing therapy is sufficient to transthoracicly deliver at least one pacing pulse, and is typically sufficient to deliver a series of pacing pulses, prior to depletion of the defibrillation energy storage source. Detection of cardiac asystole is performed following delivery of each pacing pulse, and subcutaneous pacing support is terminated in response to detecting cardiac asystole termination.

Subcutaneous cardiac stimulator employing post-shock transthoracic asystole prevention pacing

Methods and devices of cardiac electrode placement involve locating electrodes on a thorax of a patient. Surface pacing levels are determined relative to a pacing limit. Surface electrode locations are selected or rejected based on the level being within a limit. Electrodes may be relocated to new locations, and new surface pacing levels determined, until a new surface pacing level falls within the pacing limit. Selecting or rejecting electrode locations involves selecting locations suitable for implantation of subcutaneous cardiac electrodes and implanting at the selected locations. An automated method uses an array of surface electrode elements that are scanned for their associated pacing levels, such as by selecting one or more electrode element locations having the lowest pacing levels, which may correspond to locations suitable for implantation of a subcutaneous cardiac electrode and housing, a subcutaneous electrode array, a unitary subcutaneous defibrillation system, or other suitable implantable cardiac device.

Electrode placement determination for subcutaneous cardiac monitoring and therapy

Subcutaneous systems and leads may be fixed in tissue after placement by use of one or more expanding fixation elements. An expanding fixation element is provided on an implantable lead and configured to secure one or both of a subcutaneous electrode and the lead body within subcutaneous non-intrathoracic tissue. A delivery apparatus comprising a sheath may be included that is configured to introduce the lead to a desired subcutaneous non-intrathoracic location within the patient. A method of lead delivery typically involves introducing a sheath into a subcutaneous non-intrathoracic body location of a patient, providing a lead comprising a lead body and an electrode, and advancing the lead through the sheath and to the subcutaneous non-intrathoracic body location. The method further involves fixing the lead to subcutaneous non-intrathoracic tissue using an expanding fixation element and thereafter removing the sheath from the patient.

Expandable fixation elements for subcutaneous electrodes

Growing community of inventors

Isanti, MN, United States of America

Darrell Orvin Wagner